^
No biomarker
Rhabdomyosarcoma
dactinomycin
Sensitive
:
A1
No biomarker
Rhabdomyosarcoma
IE
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
VAC
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
trabectedin
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
ADX-2191
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
vinorelbine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
irinotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
SA033
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
temozolomide + irinotecan + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
cyclophosphamide + vinorelbine tartrate
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
carboplatin + etoposide oral
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
vincristine + dactinomycin
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
irinotecan + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
cyclophosphamide + topotecan
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + vincristine
Sensitive
:
A2
No biomarker
Rhabdomyosarcoma
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine
Sensitive
:
A2
PD-L1 expression
Rhabdomyosarcoma
nivolumab
Sensitive
:
C1
BRAF-MAD1L1 fusion
Rhabdomyosarcoma
anlotinib
Resistant
:
C4
PD-L1 expression
Rhabdomyosarcoma
pazopanib
Resistant
:
C4
EWSR1-TFCP2 fusion
Rhabdomyosarcoma
crizotinib
Resistant
:
C4
HRAS mutation
Rhabdomyosarcoma
tipifarnib
Sensitive
:
D
KDM1A overexpression
Rhabdomyosarcoma
SP2577
Sensitive
:
D
PAX3-FOXO1 fusion
Rhabdomyosarcoma
SNDX-275
Sensitive
:
D
HER-2 expression
Rhabdomyosarcoma
T-lymphocyte cell therapy
Sensitive
:
D